Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
SynerGIST-1st Line trial: what clinicians have said so far
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting (SynerGIST-1st Line)
- NCT07406633 ↗
- Recruiting
- Kumquat Biosciences Inc.
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on SynerGIST-1st Line yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on SynerGIST-1st Line so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 2 posts on X | |
| 1 post on Bluesky |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Multicenter, Study Evaluating the Efficacy, Safety, Tolerability, Pharmacokinetics of KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GI Stromal Tumor in 1st Line Setting
- Phase
- Phase 2
- Status
- Recruiting
- Conditions
- GIST - Gastrointestinal Stromal Tumor; GIST; GIST Metastatic Cancer; Gastro Intestinal Stromal Tumour; Gastrointestinal Tumors
- Interventions
- KQB198; Imatinib (Gleevec)
- Arms
- KQB198 in Combination with Imatinib · Experimental
- Enrollment
- 46 (estimated)
- Primary outcomes
- Objective response rate (ORR)
- Sponsor
- Kumquat Biosciences Inc.
- Start
- Jun 23, 2026
- Primary completion
- Oct 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07406633 · updated Aug 10, 2026